News >

Ibrutinib Combo Falls Short in Pancreatic Cancer

Gina Columbus @ginacolumbusonc
Published: Tuesday, Jan 22, 2019

Danelle James, MD, MAS

Danelle James, MD, MAS

The frontline combination of ibrutinib (Imbruvica) and nab-paclitaxel (Abraxane)/gemcitabine did not show a statistically significant benefit in progression-free or overall survival (OS) versus placebo plus nab-paclitaxel/gemcitabine in patients with metastatic pancreatic cancer, according to topline findings of the phase III RESOLVE (PCYC-1137) trial.1



  1. AbbVie Provides Update on Phase 3 Study of Ibrutinib (IMBRUVICA®) in Metastatic Pancreatic Cancer. AbbVie. Published January 18, 2019." . Accessed January 22, 2019.
  2. Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer (144525). website. Published September 29, 2015. Updated March 22, 2018. Accessed January 22, 2019.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication